Loading
A phase 3 trial of Trastuzumab rezetecan, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations is a phase 3 interventional study registered as NCT06430437 by Jiangsu HengRui Medicine Co., Ltd., with 300 participants planned, started 2024-07-29 and due to reach its primary completion in 2026-02. Interventions recorded: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin. Conditions listed: Non-Small Cell Lung Cancer With HER2- Mutations. No results are recorded here; the registry entry is the source.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, HER2-mutant non-small-cell lung cancer, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin, Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin.